SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Pseudo Biologist who wrote (10655)7/7/1999 10:50:00 PM
From: dwight martin  Respond to of 17367
 
From the ISIP website:

"ISIS 2302 inhibits expression of intercellular adhesion molecule 1 (ICAM-1), a molecule involved in a variety of inflammatory diseases and conditions. ISIS 2302 is in a pivotal quality trial for Crohn's disease and Phase II trials for renal transplant rejection, and ulcerative colitis. Based on results from a Phase II study in psoriasis, Isis is developing a topical formulation of ISIS 2302 in this indication and is planning an aerosol formulation for asthma."

ISIS 2302 is supposed to be a very big molecule.



To: Pseudo Biologist who wrote (10655)7/8/1999 3:10:00 PM
From: LLCF  Respond to of 17367
 
Thanks for the inspiration for this:

Subject 29311

Don't know if we'll get the input I'm hoping for, but I figured it was worth a try. Could be very useful with the right participation. Hope some folks over here are interested.

DAK